287 related articles for article (PubMed ID: 17092399)
1. Capecitabine/Cyclophosphamide/Methotrexate for patients with metastatic breast cancer: a dose-finding, feasibility, and efficacy study.
Mariani G; Petrelli F; Zambetti M; Moliterni A; Fasolo A; Marchiano A; Valagussa P; Gianni L
Clin Breast Cancer; 2006 Oct; 7(4):321-5. PubMed ID: 17092399
[TBL] [Abstract][Full Text] [Related]
2. Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results.
Michalaki V; Gennatas S; Gennatas K
Anticancer Drugs; 2009 Mar; 20(3):204-7. PubMed ID: 19174694
[TBL] [Abstract][Full Text] [Related]
3. Oral combination chemotherapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: a phase II study.
Tanaka M; Takamatsu Y; Anan K; Ohno S; Nishimura R; Yamamoto Y; Masuda N; Mitsuyama S; Tamura K;
Anticancer Drugs; 2010 Apr; 21(4):453-8. PubMed ID: 20075712
[TBL] [Abstract][Full Text] [Related]
4. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
Hainsworth JD; Jolivet J; Birch R; Hopkins LG; Greco FA
Cancer; 1997 Feb; 79(4):740-8. PubMed ID: 9024712
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer.
O'connor T; Rustum Y; Levine E; Creaven P
Cancer Chemother Pharmacol; 2008 Jan; 61(1):125-31. PubMed ID: 17426973
[TBL] [Abstract][Full Text] [Related]
6. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer.
Rossi D; Alessandroni P; Catalano V; Giordani P; Fedeli SL; Fedeli A; Baldelli AM; Casadei V; Ceccolini M; Catalano G
Clin Breast Cancer; 2007 Dec; 7(11):857-60. PubMed ID: 18269775
[TBL] [Abstract][Full Text] [Related]
7. Capecitabine in breast cancer: current status.
Smorenburg CH; Bontenbal M; Verweij J
Clin Breast Cancer; 2001 Jan; 1(4):288-93; discussion 294. PubMed ID: 11899351
[TBL] [Abstract][Full Text] [Related]
8. Cyclophosphamide, methotrexate, and chronic oral tegafur modulated by folinic acid in the treatment of patients with advanced breast carcinoma.
Ribas A; Albanell J; Solé-Calvo LA; Gallardo E; Bellmunt J; Vera R; Vidal R; Carulla J; Baselga J
Cancer; 1998 Mar; 82(5):878-85. PubMed ID: 9486577
[TBL] [Abstract][Full Text] [Related]
9. Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic offast cancer: the French experience.
Catimel G; Spielmann M; Dieras V; Tubiana-Hulin M; Bonneterre J; Pouillart P; Kayitalire L; Guastalla JP; Graffand N; Garet F; Dumortier A; Pellae-Cosset B
Semin Oncol; 1997 Feb; 24(1 Suppl 3):S8-12. PubMed ID: 9071333
[TBL] [Abstract][Full Text] [Related]
10. Capecitabine/vinorelbine: an effective and well-tolerated regimen for women with pretreated advanced-stage breast cancer.
Nolè F; Catania C; Munzone E; Rocca A; Verri E; Sanna G; Ascione G; Adamoli L; Zampino MG; Minchella I; Goldhirsch A
Clin Breast Cancer; 2006 Feb; 6(6):518-24. PubMed ID: 16595035
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes.
Campone M; Isambert N; Bourbouloux E; Roché H; Bonneterre J; Milano G; Fumoleau P
Cancer Chemother Pharmacol; 2012 Apr; 69(4):871-9. PubMed ID: 22045498
[TBL] [Abstract][Full Text] [Related]
12. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
13. Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients.
Toffoli G; Sorio R; Aita P; Crivellari D; Corona G; Bearz A; Robieux I; Colussi AM; Stocco F; Boiocchi M
Clin Cancer Res; 2000 Jun; 6(6):2279-87. PubMed ID: 10873078
[TBL] [Abstract][Full Text] [Related]
14. Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer.
Yoshimoto M; Takao S; Hirata M; Okamoto Y; Yamashita S; Kawaguchi Y; Takami M; Furusawa H; Morita S; Abe C; Sakamoto J
Cancer Chemother Pharmacol; 2012 Aug; 70(2):331-8. PubMed ID: 22526409
[TBL] [Abstract][Full Text] [Related]
15. Dosage of capecitabine and cyclophosphamide combination therapy in patients with metastatic breast cancer.
Ohno S; Mitsuyama S; Tamura K; Nishimura R; Tanaka M; Hamada Y; Kuroki S;
Anticancer Res; 2007; 27(2):1009-13. PubMed ID: 17465235
[TBL] [Abstract][Full Text] [Related]
16. A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study.
Villanueva C; Awada A; Campone M; Machiels JP; Besse T; Magherini E; Dubin F; Semiond D; Pivot X
Eur J Cancer; 2011 May; 47(7):1037-45. PubMed ID: 21339064
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of a combination of vinorelbine, cyclophosphamide and 5-fluorouracil in the treatment of advanced breast cancer.
Ardavanis A; Extra JM; Espié M; Cuvier C; Marty M
In Vivo; 1998; 12(5):559-62. PubMed ID: 9827368
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer.
Blum JL; Dees EC; Chacko A; Doane L; Ethirajan S; Hopkins J; McMahon R; Merten S; Negron A; Neubauer M; Ilegbodu D; Boehm KA; Asmar L; O'Shaughnessy JA
J Clin Oncol; 2006 Sep; 24(27):4384-90. PubMed ID: 16926223
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II study with paclitaxel in combination with weekly high-dose 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer: an interim analysis.
Klaassen U; Wilke H; Pari CP; Strumberg D; Harstrick A; Eberhardt W; Becher R; Diergarten K; Seeber S
Semin Oncol; 1995 Dec; 22(6 Suppl 14):7-11. PubMed ID: 8553083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
